The ACME Laboratories Ltd. (DSE:ACMELAB)
Bangladesh · Delayed Price · Currency is BDT 79.50
-1.00 (-1.24%)
At close: Jun 16, 2026
The ACME Laboratories Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 40,045 | 35,937 | 31,932 | 26,948 | 23,858 | 20,770 | |
Revenue Growth (YoY) | 15.25% | 12.54% | 18.50% | 12.95% | 14.87% | 9.29% |
Cost of Revenue | 23,405 | 20,795 | 18,715 | 16,045 | 14,458 | 12,772 |
Gross Profit | 16,641 | 15,142 | 13,216 | 10,902 | 9,401 | 7,998 |
Selling, General & Admin | 9,930 | 8,534 | 7,539 | 6,424 | 5,381 | 4,457 |
Other Operating Expenses | 3.9 | 3.9 | 3.9 | 3.89 | 3.73 | -96.44 |
Operating Expenses | 9,934 | 8,538 | 7,543 | 6,428 | 5,385 | 4,360 |
Operating Income | 6,707 | 6,603 | 5,673 | 4,474 | 4,016 | 3,638 |
Interest Expense | -3,136 | -3,238 | -2,283 | -1,426 | -1,293 | -1,585 |
Interest & Investment Income | 11.95 | 11.95 | 5.55 | 6.99 | 5.73 | 18.01 |
Currency Exchange Gain (Loss) | -108.25 | -108.25 | -388.43 | -197.48 | -91.93 | 18.62 |
Other Non Operating Income (Expenses) | 102.88 | 95.63 | 199.91 | 32.71 | 55.34 | -16.38 |
EBT Excluding Unusual Items | 3,577 | 3,365 | 3,207 | 2,891 | 2,692 | 2,073 |
Gain (Loss) on Sale of Assets | -9.41 | -9.41 | -3.94 | 3.86 | 1.31 | 0.18 |
Asset Writedown | - | - | - | -1.37 | - | - |
Other Unusual Items | 4.3 | 4.3 | 0.65 | - | - | - |
Pretax Income | 3,572 | 3,360 | 3,204 | 2,893 | 2,693 | 2,073 |
Income Tax Expense | 906.27 | 931.25 | 747.54 | 589.65 | 582.25 | 504.27 |
Net Income | 2,666 | 2,429 | 2,456 | 2,304 | 2,111 | 1,569 |
Net Income to Common | 2,666 | 2,429 | 2,456 | 2,304 | 2,111 | 1,569 |
Net Income Growth | 10.93% | -1.12% | 6.62% | 9.13% | 34.52% | 8.19% |
Shares Outstanding (Basic) | 212 | 212 | 212 | 212 | 212 | 212 |
Shares Outstanding (Diluted) | 212 | 212 | 212 | 212 | 212 | 212 |
Shares Change (YoY) | 0.00% | - | - | - | - | - |
EPS (Basic) | 12.60 | 11.48 | 11.61 | 10.89 | 9.98 | 7.42 |
EPS (Diluted) | 12.60 | 11.48 | 11.61 | 10.89 | 9.98 | 7.42 |
EPS Growth | 10.92% | -1.12% | 6.62% | 9.13% | 34.52% | 8.26% |
Free Cash Flow | 3,167 | 101.99 | -2,162 | -4,001 | -615.35 | 915.26 |
Free Cash Flow Per Share | 14.96 | 0.48 | -10.22 | -18.91 | -2.91 | 4.33 |
Dividend Per Share | 3.500 | 3.500 | 3.500 | 3.300 | 3.000 | 2.500 |
Dividend Growth | - | - | 6.06% | 10.00% | 20.00% | - |
Gross Margin | 41.55% | 42.13% | 41.39% | 40.46% | 39.40% | 38.51% |
Operating Margin | 16.75% | 18.38% | 17.77% | 16.60% | 16.83% | 17.52% |
Profit Margin | 6.66% | 6.76% | 7.69% | 8.55% | 8.85% | 7.56% |
Free Cash Flow Margin | 7.91% | 0.28% | -6.77% | -14.85% | -2.58% | 4.41% |
EBITDA | 8,878 | 8,442 | 7,227 | 5,882 | 5,368 | 4,970 |
EBITDA Margin | 22.17% | 23.49% | 22.63% | 21.83% | 22.50% | 23.93% |
D&A For EBITDA | 2,171 | 1,839 | 1,554 | 1,407 | 1,352 | 1,332 |
EBIT | 6,707 | 6,603 | 5,673 | 4,474 | 4,016 | 3,638 |
EBIT Margin | 16.75% | 18.38% | 17.77% | 16.60% | 16.83% | 17.52% |
Effective Tax Rate | 25.37% | 27.72% | 23.33% | 20.38% | 21.62% | 24.32% |
Advertising Expenses | - | 196.15 | 178.77 | 146.59 | 138.99 | - |